Real‐World Survival Outcomes of Patients With High PD‐L1 Advanced NSCLC Who Received Chemoimmunotherapy Versus Immunotherapy
In patients with PD-L1 ≥ 50% advanced NSCLC, addition of chemo to first-line pembro yielded a higher ORR but no additional benefit in PFS or OS, supporting a shared-decision approach. However, higher rates of hospitalizations seen in the pembro-chemo group should warrant caution in use.
Authors
- Annette Tognela (ORCID: https://orcid.org/0000-0003-0875-4352)
- Po Yee Yip (ORCID: https://orcid.org/0000-0003-2843-1286)
- Victoria Bray (ORCID: https://orcid.org/0000-0002-6357-3899)
- Peey‐Sei Kok (ORCID: https://orcid.org/0000-0002-4910-4615)
- Junipearl Cheng
- C. McKay
Institutions
- Camden and Campbelltown Hospitals (AU)
- The University of Sydney (AU)
- Liverpool Hospital (AU)
- Cooperative Trials Group for Neuro-Oncology (AU)
- National Health and Medical Research Council (AU)
- Western Sydney University (AU)
Publication Details
- Journal
- Asia-Pacific Journal of Clinical Oncology
- Published
- 2025-06-17
- DOI
- https://doi.org/10.1111/ajco.14205
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Western Sydney University